Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Operations: 2016-2024

Historic Cash from Operations for Krystal Biotech (KRYS) over the last 9 years, with Dec 2024 value amounting to $123.4 million.

  • Krystal Biotech's Cash from Operations fell 32.62% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.2 million, marking a year-over-year increase of 178.16%. This contributed to the annual value of $123.4 million for FY2024, which is 238.98% up from last year.
  • Krystal Biotech's Cash from Operations amounted to $123.4 million in FY2024, which was up 238.98% from -$88.8 million recorded in FY2023.
  • Krystal Biotech's Cash from Operations' 5-year high stood at $123.4 million during FY2024, with a 5-year trough of -$100.6 million in FY2022.
  • Its 3-year average for Cash from Operations is -$22.0 million, with a median of -$88.8 million in 2023.
  • In the last 5 years, Krystal Biotech's Cash from Operations crashed by 109.79% in 2022 and then soared by 238.98% in 2024.
  • Krystal Biotech's Cash from Operations (Yearly) stood at -$26.1 million in 2020, then tumbled by 83.79% to -$47.9 million in 2021, then crashed by 109.79% to -$100.6 million in 2022, then grew by 11.70% to -$88.8 million in 2023, then soared by 238.98% to $123.4 million in 2024.